BMS’s Opdivo On Track For Esophageal Cancer Indication

Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.

https://scrip.pharmaintelligence.informa.com/SC125951/BMSs-Opdivo-On-Track-For-Esophageal-Cancer-Indication

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *